Impact of Size and Location of Metastases on Early Tumor Shrinkage and Depth of Response in Patients With Metastatic Colorectal Cancer: Subgroup Findings of the Randomized, Open-Label Phase 3 Trial FIRE-3/AIO KRK-0306

2020 ◽  
Vol 19 (4) ◽  
pp. 291-300.e5
Author(s):  
Matthias F. Froelich ◽  
Elina L. Petersen ◽  
Volker Heinemann ◽  
Dominik Nörenberg ◽  
Nina Hesse ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Tumor Shrinkage ◽  
Open Label ◽  
Phase 3 ◽  
Depth Of Response ◽  
Early Tumor Shrinkage ◽  
Open Label Phase ◽  
Early Tumor

scholarly journals Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors

2021 ◽  
Vol 9 (4) ◽  
pp. e002501
Author(s):  
Giovanni Fucà ◽  
Francesca Corti ◽  
Margherita Ambrosini ◽  
Rossana Intini ◽  
Massimiliano Salati ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Relative Reduction ◽  
Tumor Shrinkage ◽  
Depth Of Response ◽  
Early Tumor Shrinkage ◽  
Early Tumor

BackgroundImmune checkpoint inhibitors (ICIs) are the new standard of care in microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC). Since tumor response dynamic parameters already shown a strong association with survival outcomes in patients with mCRC treated with first-line therapy, we investigated the association of early tumor shrinkage (ETS) and depth of response (DoR) in patients with MSI-H/dMMR mCRC treated with ICIs.MethodsThis is a retrospective, multicenter, cohort study in patients with dMMR and/or MSI-high mCRC treated with ICIs (anti-PD-1/PD-L1 with or without anti-CTLA-4 agents) with measurable disease and at least one post-baseline radiological disease reassessment. The Kaplan-Meier method and Cox proportional-hazards regression models were used for survival analyses. A maximally selected statistics method in a Cox regression model for progression-free survival (PFS) was used to determine the optimal cut-offs for ETS and DoR.ResultsWe included a total of 169 patients: 116 (68.6%) were treated with anti-PD-1 monotherapy, whereas 53 (31.4%) with anti-PD-1 plus anti-CTLA-4 agents. Patients with primary progressive disease (N=37, 21.9%), experienced an extremely poor overall survival (OS) and were evaluated separately. In patients with clinical benefit, we observed a significant association between ETS and DoR with both OS and PFS, and we identified a relative reduction of at least 1% as the optimal cut-off for ETS and a relative reduction of at least 50% as the optimal cut-off for DoR.ConclusionsETS and DoR are important prognostic factors in patients with MSI-high mCRC treated with ICIs that might be useful to design treatment intensification/deintensification strategies. A prospective validation of both is warranted.

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

2014 ◽  
Vol 15 (10) ◽  
pp. 1065-1075 ◽  
Author(s):  
Volker Heinemann ◽  
Ludwig Fischer von Weikersthal ◽  
Thomas Decker ◽  
Alexander Kiani ◽  
Ursula Vehling-Kaiser ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Line Treatment ◽  
First Line ◽  
Open Label ◽  
Phase 3 ◽  
Open Label Phase ◽  
First Line Treatment

scholarly journals Early tumor shrinkage in metastatic colorectal cancer: Retrospective analysis from an irinotecan-based randomized first-line trial

2013 ◽  
Vol 104 (6) ◽  
pp. 718-724 ◽  
Author(s):  
Clemens Giessen ◽  
Ruediger P. Laubender ◽  
Ludwig Fischer von Weikersthal ◽  
Andreas Schalhorn ◽  
Dominik P. Modest ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Retrospective Analysis ◽  
Tumor Shrinkage ◽  
First Line ◽  
Early Tumor Shrinkage ◽  
Early Tumor

Predictive biomarker analysis of early tumor shrinkage induced by FOLFIRI+Bev for patients with metastatic colorectal cancer in WJOG4407G study.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e14616-e14616
Author(s):  
Yasushi Tsuji ◽  
Kentaro Yamazaki ◽  
Mari Saito Oba ◽  
Kazuko Sakai ◽  
Michitaka Nagase ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Predictive Biomarker ◽  
Tumor Shrinkage ◽  
Early Tumor Shrinkage ◽  
Biomarker Analysis ◽  
Early Tumor
Sign in / Sign up

Export Citation Format

Share Document